European heart journal. Acute cardiovascular care
A Multicentre Observational Study on Landiolol Use, Efficacy, and Safety in European Patients with Supraventricular Arrhythmia (Landi-UP).
Al-Medina Dizdarevic, Marek Šramko, Norman Mangner, Béla Merkely, Endre Zima, Nikolaou Nikolaos, Daniel Scherr, Johann Knotzer, Paul Köglberger, Zoi Nouvaki, Martin Martinek, Tomas Hnat, Carina Bethlehem, Zlatko Fras, Waldemar Goździk
Published: 202510.1093/ehjacc/zuaf129
Abstract
BACKGROUND AND AIMS: Landiolol is an ultrashort-acting, highly cardio-selective beta1-adrenergic receptor blocker used for short-term control of tachyarrhythmias. While its real-world use has been described in Japan, data from European clinical pract…
Preview only. Read the full abstract at the source